The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Open accessAbstract
BACKGROUND: The discovery of low-frequency coding variants affecting the risk of coronary artery disease has facilitated the identification of therapeutic targets. METHODS: Through DNA genotyping, we tested 54,003 coding-sequence variants covering 13,715 human genes in up to 72,868 patients with coronary artery disease and 120,770 controls who did not have coronary artery disease. Through DNA sequencing, we studied the effects of loss-of-function mutations in selected genes. RESULTS: We confirmed previously observed significant associations between coronary artery disease and low-frequency missense variants in the genes LPA and PCSK9. We also found significant associations between coronary artery disease and low-frequency missense variants in the genes SVEP1 (p.D2702G; minor-allele frequency, 3.60%; odds ratio for disease, 1.14; P=4.2×10(-10)) and ANGPTL4 (p.E40K; minor-allele frequency, 2.01%; odds ratio, 0.86; P=4.0×10(-8)), which encodes angiopoietin-like 4. Through sequencing of ANGPTL4, we identified 9 carriers of loss-of-function mutations among 6924 patients with myocardial infarction, as compared with 19 carriers among 6834 controls (odds ratio, 0.47; P=0.04); carriers of ANGPTL4 loss-of-function alleles had triglyceride levels that were 35% lower than the levels among persons who did not carry a loss-of-function allele (P=0.003). ANGPTL4 inhibits lipoprotein lipase; we therefore searched for mutations in LPL and identified a loss-of-function variant that was associated with an increased risk of coronary artery disease (p.D36N; minor-allele frequency, 1.9%; odds ratio, 1.13; P=2.0×10(-4)) and a gain-of-function variant that was associated with protection from coronary artery disease (p.S447*; minor-allele frequency, 9.9%; odds ratio, 0.94; P=2.5×10(-7)). CONCLUSIONS: We found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride levels that were lower than those among noncarriers; these mutations were also associated with protection from coronary artery disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ANGPTL4 loss-of-function mutations in humans are associated with lower plasma triglycerides (40, 56–58).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, multiple studies found that individuals deficient in one of these three ANGPTL proteins have a lower risk of cardiovascular disease (56, 57, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [57]
In the citing paper
“large-scale genetic studies have shown that individuals carrying loss-of-function mutations in ANGPTL4 exhibit a lower risk of coronary artery disease compared to noncarriers [34,35].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [34]
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“Similarly, heterozygous LOF variants in ANGPTL311 and ANGPTL412 genes are associated with reductions both in plasma TG and ASCVD risk.”
From Clinical review on triglycerides (2020) · cites this paper as [12]
In the citing paper
“Genetically attenuated ANGPTL4 is associated with favourable lipid and glycaemia profiles, and with reduced ASCVD risk.12,99”
From Clinical review on triglycerides (2020) · cites this paper as [12]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [29]
In the citing paper
“Like mice, humans deficient in ANGPTL3, ANGPTL4, or ANGPTL8 have lower plasma triglycerides (56–58, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies (2011) · Nature · doi:10.1038/nature10405 · Cited by 2,033
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650
A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease
Nikpay, M., Goel, A., Won, H., Hall, L. M., Willenborg, C., Kanoni, S., Saleheen, D., Kyriakou, T., Nelson, C. P., Hopewell, J. C., et al. (2015) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 581
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 497
Musunuru, K., Arora, P. K., Cooke, J. P., Ferguson, J. F., Hershberger, R. E., Hickey, K. T., Lee, J., Lima, J. A. C., Loscalzo, J., Pereira, N. L., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000046 · Cited by 14
Zhang, J., Chen, G., Liang, S., Liu, J., Zhang, J., Shen, H., Chen, Y., Duan, J., & Sun, Z. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.147604 · Cited by 12
Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs
Cui, H. S., Zuo, S., Liu, Z., Liu, H., Wang, J., You, T., Zheng, Z., Zhou, Y., Qian, X., Yao, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb8543 · Cited by 13
Schinzari, F., Vizioli, G., Campia, U., Tesauro, M., & Cardillo, C. (2021) · Biomedicines · doi:10.3390/biomedicines9081037 · Cited by 13
Andrews, S. L., Najafabadi, M. G., Gong, P., Shamkhi, N., Carleton, L., Schofield, C., Kessler, T., Samani, N. J., Webb, T. R., & Morris, G. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119479 · Cited by 12
Bioactive matters based on natural product for cardiovascular diseases
Zhong, L., Tan, X., Yang, W., Li, P., Ye, L., Luo, Q., & Hou, H. (2024) · Smart Materials in Medicine · doi:10.1016/j.smaim.2024.11.001 · Cited by 12
Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities
Gunn, K. H., Gutgsell, A. R., Xu, Y., Johnson, C. V., Liu, J., & Neher, S. B. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100312 · Cited by 12
Wang, M., Lee-Kim, V. S., Atri, D. S., Elowe, N. H., Yu, J., Garvie, C. W., Won, H., Hadaya, J. E., MacDonald, B. T., Trindade, K., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003399 · Cited by 12
Hellstrand, S., Ericson, U., Schulz, C., Drake, I., Gullberg, B., Hedblad, B., Engström, G., Orho‐Melander, M., & Sonestedt, E. (2016) · Genes & Nutrition · doi:10.1186/s12263-016-0536-0 · Cited by 12
Liu, C., Gaudet, D., & Miller, Y. I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169939 · Cited by 11
Silbernagel, G., Scharnagl, H., Kleber, M. E., Stojaković, T., & März, W. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317693938 · Cited by 12
Detecting Clustered Independent Rare Variant Associations Using Genetic Algorithms
Guevara-Souza, M., Vallejo, E. E., & Estrada, K. (2019) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2930505 · Cited by 12
Targeting ADAMTS-7: A Vaccination Against Atherosclerosis—and Its Complications?
Kessler, T., & Schunkert, H. (2023) · Circulation · doi:10.1161/circulationaha.122.063495 · Cited by 12
Chip-DSF: A rapid screening strategy for drug protein targets
Cui, Z., Chen, P., Li, C., Deng, S., & Yang, H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106346 · Cited by 11
ANGPTL4-the Link Binding Lipid Metabolism and Inflammation
Zhang, Y., Liang, J., Li, Z., Zuo, Y., & Dai, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673320024240829070906 · Cited by 11
From Cells to Plaques: The Molecular Pathways of Coronary Artery Calcification and Disease
Mitsis, A., Khattab, E., Christodoulou, E., Myrianthopoulos, K., Myrianthefs, M. M., Tzikas, S., Ziakas, A., Fragakis, N., & Kassimis, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216352 · Cited by 13
Early growth response-1, a dynamic conduit in cardiovascular disease
Khachigian, L. M. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1487668 · Cited by 10
Borén, J., Packard, C. J., Nordestgaard, B. G., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf214 · Cited by 12
Zhang, Y., & Karakikes, I. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.008 · Cited by 13
Genética de la cardiopatía isquémica: del conocimiento actual a las implicaciones clínicas
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.02.033 · Cited by 11
Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study
Bebu, I., Keshavarzi, S., Gao, X., Braffett, B. H., Canty, A. J., Herman, W. H., Orchard, T. J., Dagogo-Jack, S. E., Nathan, D. M., Lachin, J. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2388 · Cited by 11
Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization
Xu, D., Lu, J., Yang, Y., Hu, W., Chen, J., Xue, J., Yang, S., Cao, N., Hu, H., Qian, N., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119110 · Cited by 10
Polygenic Risk Score Assessment for Coronary Artery Disease in Asian Indians
Rout, M., Tung, G. K., Singh, J. R., Mehra, N. K., Wander, G. S., Ralhan, S. K., & Sanghera, D. K. (2024) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10511-z · Cited by 10
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Mortensen, M. B., Langsted, A., Nordestgaard, B. G., & Afzal, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120471 · Cited by 13
Kelly, M. S., Beavers, C. J., Bucheit, J. D., Sisson, E. M., & Dixon, D. L. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.05.014 · Cited by 10
Exceptional Longevity and Polygenic Risk for Cardiovascular Health
Revelas, M., Thalamuthu, A., Oldmeadow, C. J., Evans, T., Armstrong, N. J., Riveros, C., Kwok, J. B., Schofield, P. R., Brodaty, H., Scott, R. J., et al. (2019) · Genes · doi:10.3390/genes10030227 · Cited by 10
Khounphinith, E., Yin, R., Cao, X., Huang, F., Wu, J., & Li, H. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.31729 · Cited by 9
Wang, J., Ma, X., Zhang, Q., Chen, Y., Wu, D., Zhao, P., & Yu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665514 · Cited by 11
Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response
Dai, Q., Liu, X., He, T., Yang, C., Jiang, J., Fang, Y., Fu, Z., Yuan, Y., Bai, S., Qiu, T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103170 · Cited by 10
Khera, A. V., Wang, M., Chaffin, M. D., Emdin, C. A., Samani, N. J., Schunkert, H., Watkins, H. C., McPherson, R., Erdmann, J., Elosúa, R., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003598 · Cited by 10
In the Beginning, Lipoproteins Cross the Endothelial Barrier
Goldberg, I. J., Cabodevilla, A. G., & Younis, W. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22017 · Cited by 10
Leander, K., Chen, Y., Vikström, M., Silveira, A. M. V., Fisher, R. M., Konrad, R. J., & Hooft, F. M. V. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321308 · Cited by 8
Systems Medicine as an Emerging Tool for Cardiovascular Genetics
Haase, T., Börnigen, D., Müller, C., & Zeller, T. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00027 · Cited by 9
Hahn, J. M., Fu, Y., Brown, M. R., Bis, J. C., de Vries, P. S., Feitosa, M. F., Yanek, L. R., Weiß, S., Giulianini, F., Smith, A. V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230035 · Cited by 9
Jung, I., Elenbaas, J. S., Burks, K. H., Amrute, J., Xiangyu, Z., Alisio, A. E., & Stitziel, N. O. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.09.015 · Cited by 9
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 11
Coding and regulatory variants affect serum protein levels and common diseasePreprint
Emilsson, V., Guðmundsdóttir, V., Guðjónsson, A., Karim, M. A., Ilkov, M., Staley, J. R., Gudmundsson, E. F., Jonsson, B. G., Launer, L. J., Lindeman, J. H. N., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.06.080440 · Cited by 9
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Genetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 8
Svep1 stabilises developmental vascular anastomosis in reduced flow conditions
Coxam, B., Collins, R., Hußmann, M., Huisman, Y., Meier, K., Jung, S., Bartels‐Klein, E., Szymborska, A., Finotto, L., Helker, C. S., et al. (2022) · Development · doi:10.1242/dev.199858 · Cited by 9
Deng, H., Li, J., Shah, A. A., Ge, L., & Ouyang, W. (2023) · Genomics · doi:10.1016/j.ygeno.2023.110567 · Cited by 8
Das, S. S., Kar, A., Rajkumar, S., Lee, S. H., Alvarez, M., Pietiläinen, K. H., & Pajukanta, P. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319358 · Cited by 8
Discovery platforms for RNA therapeutics
Ciucci, G., Braga, L., & Zacchigna, S. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16424 · Cited by 8
Kawaratani, H., Sawai, H., Onishi, M., Kogiso, T., Shimada, N., Uojima, H., Nakajima, T., Matsumoto, N., Ikejima, K., Ishikawa, T., et al. (2021) · Liver International · doi:10.1111/liv.15022 · Cited by 8
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 8
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.003 · Cited by 14
Unraveling the complex genetics of coronary artery disease
Kovacic, J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.007 · Cited by 7
A practical guide to the management of dyslipidaemia
Siegel, P. M., Katzmann, J. L., Weinmann‐Menke, J., Landmesser, U., Schunkert, H., Baldus, S. E., Böhm, M., Laufs, U., Lüscher, T. F., & Hilgendorf, I. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02833-y · Cited by 10
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Yokote, K., Niwa, K., Hakoda, T., Oh, F., Kajimoto, Y., Fukui, T., Kim, H., Noda, Y., Lundström, T., & Yajima, T. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-0358 · Cited by 7
Reyes‐Soffer, G. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000619 · Cited by 13
Angiopoietin-like Proteins in Colorectal Cancer—A Literature Review
Zajkowska, M., & Mroczko, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168439 · Cited by 7
Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy
Yeoh, S. G., Sum, J.-S., Lai, J. Y., Isa, W. Y. H. W., & Lim, T. S. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10169-x · Cited by 7
Kurooka, N., Eguchi, J., Murakami, K., Kamei, S., Kikutsuji, T., Sasaki, S., Seki, A., Yamaguchi, S., Nojima, I., Watanabe, M., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.01.006 · Cited by 6
He, D., Huang, L., Xu, Y., Pan, X., & Liu, L. (2016) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720016500281 · Cited by 7
Gruppen, E. G., Kersten, S., & Dullaart, R. P. F. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0717-5 · Cited by 7
Novel GPIHBP1-independent pathway for clearance of plasma TGs in Angptl4−/−Gpihbp1−/− mice
Cushing, E. M., Sylvers, K. L., Chi, X., Shetty, S. K., & Davies, B. J. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m084749 · Cited by 10
Polymorphisms in ANGPTL4 link triglycerides with CAD
Lim, G. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.46 · Cited by 7
Angeborene Störungen im Lipoproteinstoffwechsel
März, W., Grammer, T. B., Delgado, G., & Kleber, M. E. (2017) · Herz · doi:10.1007/s00059-017-4578-x · Cited by 7
Nguyen, Q. H., Lukowski, S. W., Chiu, H. S., Friedman, C. E., Senabouth, A., Crowhurst, L., Bruxmer, T. J. C., Christ, A. N., Palpant, N. J., & Powell, J. E. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/229336 · Cited by 7
Biswas, A., Arshid, S., Kristensen, K. K., Jørgensen, T. J. D., & Ploug, M. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100745 · Cited by 6
Huangfu, G., Chan, D. C., Pang, J., Jaltotage, B., Watts, G. F., Lan, N. S. R., Bell, D. A., Ihdayhid, A. R., Ayonrinde, O. T., & Dwivedi, G. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.013 · Cited by 7
Yu, F., Liu, F., Li, X., Zhao, Q., Luo, J., Zhang, J., & Yang, Y. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02630-9 · Cited by 6
Osawa, I., Akita, K., Hasegawa, K., Fifer, M. A., Tower-Rader, A. F., Reilly, M. P., Maurer, M. S., Stitziel, N. O., Javaheri, A., & Shimada, Y. J. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012343 · Cited by 7
Gagnon, É., Gill, D., Chabot, D., Cronjé, H. T., Yuan, S., Brennan, S., Thériault, S., Burgess, S., Arsenault, B. J., & Dib, M. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004933 · Cited by 10
Doria, A. (2019) · Diabetes · doi:10.2337/dbi18-0036 · Cited by 6
Paik, H., Lee, J., Jeong, C.-S., Park, J. S., Lee, J. H., Rappoport, N., Kim, Y., Sohn, H., Jo, C., Kim, J., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02144-0 · Cited by 6
Nitro-fatty acids: mechanisms of action, roles in metabolic diseases, and therapeutics
Ni, H., Tan, X., Du, J., & Wang, Y. (2024) · Current Medicine · doi:10.1007/s44194-024-00030-z · Cited by 6
Chang, Y., Shah, T., Yang, J. W., & Min, D. I. (2016) · Transplant Immunology · doi:10.1016/j.trim.2016.11.002 · Cited by 6
Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki, K. C., & Dicklin, M. R. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000741 · Cited by 6
Dang, R., Qu, B., Guo, K., Zhou, S., Sun, H., Wang, W., Han, J., Feng, K., Lin, J., & Hu, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.818813 · Cited by 7
Brænne, I., Zeng, L., Willenborg, C., Tragante, V., Kessler, T., Willer, C. J., Laakso, M., Wallentin, L. C., Franks, P. W., Salomaa, V. V., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182999 · Cited by 6
Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
Lechner, K., Kessler, T., & Schunkert, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01408-9 · Cited by 6
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Folia Cardiologica · doi:10.5603/fc.2021.0005 · Cited by 6
Silbernagel, G., Higbie, H., Meininger, T., Lemen, D., Li, H., Chen, Y., Wen, Y., Zhen, Y., Qian, Y., Korovianskaia, P., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120485 · Cited by 5
Hsu, P. W.-C., Yeh, C., Lo, C.-J., Tsai, T.-H., Chan, Y.-H., Chou, Y.-J., Yang, N.-I., Cheng, M., Sheu, W. H., Lai, C., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00821-y · Cited by 5
Cabodevilla, A. G., Izquierdo, M. C., Basu, D., Younis, W., Tirumalasetty, M. B., Miao, Q. R., Nasias, D., Kanter, J. E., Ho, T. W. W., Gjini, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68193-3 · Cited by 5
Kim, J., Choi, S. W., Lee, Y., Lee, J., Chung, H., Woo, J. S., Kim, W.-S., Choi, Y. Y., & Kim, W. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s374372 · Cited by 5
Tian, Q., Chen, J.-H., Ding, Y., Wang, X., Qiu, J.-Y., Cao, Q., Zhuang, L., Jin, R., & Zhou, G.-P. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09322-x · Cited by 5
Lee, J.-Y., Moon, S., Kim, Y. K., Lee, S., Lee, B.-S., Park, M., Park, J. E., Jang, Y., & Han, B. (2017) · Journal of Genetics · doi:10.1007/s12041-017-0854-z · Cited by 6
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5
Khan, M. S., Ishaq, M., Ayub, M. T., Rehman, A. U., Hayes, J. J., Mortada, M. E., & Biederman, R. W. (2021) · Journal of Lipids · doi:10.1155/2021/6696915 · Cited by 6
Kuchenbaecker, K. B., Gilly, A., Süveges, D., Southam, L., Giannakopoulou, O., Kilian, B., Tsafantakis, E., Karaleftheri, M., Farmaki, A., Gurdasani, D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04436-9 · Cited by 7
Deep Apolipoprotein Proteomics to Uncover Mechanisms of Coronary Disease Risk ∗
Rader, D. J., Bajaj, A., & Khetarpal, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.066 · Cited by 5
Remnant Lipoproteins as a Target for Atherosclerosis Risk Reduction
Levin, M. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316341 · Cited by 5
Genome Editing in Dyslipidemia and Atherosclerosis
Chen, Z., Lehertshuber, C., & Schunkert, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_10 · Cited by 8
Ahn, J. H., Kim, M. C., Ahn, Y., Cho, D. I., Lim, Y., Hyun, D. Y., Lee, S. H., Cho, K. H., Cho, M., Kim, Y. S., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131164 · Cited by 4
DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases
Rakicevic, L. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082141 · Cited by 4
Zhang, T., Hou, Y., Liu, M., Hou, X., Tang, Y. P., Ren, L., & Song, G. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s438757 · Cited by 4
Jin, Y.-J., Wu, X.-Y., & An, Z. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507262 · Cited by 5
To absorb fat — supersize my lipid droplets
Goldberg, I. J., & Hussain, M. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125318 · Cited by 4
Blood platelet surface receptor genetic variation and risk of thrombotic episodes
Szelenberger, R., Kacprzak, M., Bijak, M., Saluk, J., & Zielińska, M. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.06.020 · Cited by 4
Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis
Scheja, L., & Heeren, J. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_363 · Cited by 4
Xiang, Q., Liu, Z., Mu, G., Xie, Q., Zhang, H., Zhou, S., Wang, Z., Guo, N., Huang, J., Jiang, J., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01154-6 · Cited by 4
Pharmacogenomic approaches to lipid-regulating trials
Bertrand, M.-J., Dubé, M., & Tardif, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000351 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.12.001 · Cited by 4
The Genetics of Dyslipidemia — When Less Is More
Kersten, S. (2016) · New England Journal of Medicine · doi:10.1056/nejme1601117 · Cited by 4
Metadata
- Authors
- Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators
- Corresponding author
- Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-24
- Volume
- 374
- Issue
- 12
- Pages
- 1134-1144
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4850838
- OpenAlex
- W2294822677
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 26 · 2023: 26 · 2022: 50 · 2021: 63 · 2020: 58 · 2019: 52 · 2018: 58 · 2017: 69 · 2016: 44
- FWCI
- 60.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Figshare (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- American Heart Association
- Massachusetts General Hospital (R01HL107816)
- Foundation for Barnes-Jewish Hospital
- Donovan Family Foundation
- University of Dundee
- Queen Mary University of London
- Wellcome Trust (098381, 090532, 090532/Z/09/Z, 090532/Z/09/)
- Deutsches Zentrum für Herz-Kreislaufforschung
- Massachusetts Medical Society
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research (NF-SI-0512-10165, NF-SI-0611-10170, NF-SI-0611-10099)
- British Heart Foundation (090532/Z/09/Z, RG/13/13/30194, RG/08/014/24067, RG/14/5/30893)
- University of Leicester
- University College London
- University of Oxford
- European Commission (EU-FP7, 261123, 098381)
- University of Glasgow
- Deutsche Forschungsgemeinschaft (SFB1123)
- Fondation Leducq (12CVD02)
- Universiteit van Amsterdam
- Bundesministerium für Bildung und Forschung
- Ministero della Salute
- Novo Nordisk Fonden (NNF16OC0021370, NNF14OC0011049, NNF15OC0016320)
- Exzellenzclusters Entzündungsforschung
- National Institutes of Health (UL1TR001070)
- Medical Research Council (MC_UU_12015/1, MR/N005813/1, MC_PC_13048, EU FP7, MR/L003120/1)
- Barts and The London School of Medicine and Dentistry
- National Heart, Lung, and Blood Institute (R01HL127564, K08HL114642, K01HL125751, R01HL107816)
- National Human Genome Research Institute (U01HG008672)
- National Cancer Institute (R25CA094880)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- coronary artery disease, ANGPTL4, lipoprotein lipase, SVEP1, missense mutations, loss-of-function mutations, gain-of-function mutations, myocardial infarction, triglyceride levels, PCSK9, LPA, genetic risk factors, triglyceride lowering
- MeSH terms
- Angiopoietin-Like Protein 4, Aged, Coronary Artery Disease, Female, Humans, Lipoprotein Lipase, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Cell Adhesion Molecules, Sequence Analysis, DNA, Mutation, Missense, Angiopoietins, Genotyping Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
